Primary malignant mesodermal ovarian sarcomas.
Primary malignant mesodermal ovarian sarcomas are rare tumors and have a poor prognosis. The disease is usually diagnosed at a late stage and 5-year survivals are uncommon. Most patients are treated with debulking surgery followed by adjuvant chemotherapy. We report ten patients treated at a single institution. All patients underwent surgery and 90% received adjuvant chemotherapy. The median survival was 20 months, and only one patient survived beyond 5 years. Newer treatment strategies are urgently needed in the management of this disease.
Gari
A
A
Department of Gynecology, McGill University, Montreal, Quebec, Canada.
Souhami
L
L
Arseneau
J
J
Stanimir
G
G
D000328:Adult; D000368:Aged; D002423:Cause of Death; D017024:Chemotherapy, Adjuvant; D015331:Cohort Studies; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D018199:Mixed Tumor, Mesodermal / Q000401:mortality* / Q000473:pathology* / Q000628:therapy; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000401:mortality* / Q000473:pathology* / Q000628:therapy; D010052:Ovariectomy / Q000379:methods; D011379:Prognosis; D018570:Risk Assessment; D016019:Survival Analysis; D013997:Time Factors